Patient clinicopathologic characteristics in Stockholm and multi-institutional cohorts
| Stockholm untreated (n = 283) | Stockholm TAM-treated (n = 317) | Multi-institutional (n = 358) | |
|---|---|---|---|
| Age at surgery, y | |||
| <50 | 4 (1%) | 2 (<1%) | 108 (30%) |
| 50–59 | 92 (33%) | 89 (28%) | 113 (32%) |
| 60–69 | 178 (63%) | 214 (68%) | 93 (26%) |
| ≥70 | 9 (3%) | 12 (4%) | 44 (12%) |
| Tumor size | |||
| ≤20 mm | 230 (81%) | 259 (82%) | 237 (66%) |
| >20 mm | 51 (18%) | 55 (17%) | 121 (34%) |
| Unknown | 2 (1%) | 3 (1%) | 0 |
| Tumor grade | |||
| Well | 69 (24%) | 67 (21%) | 82 (23%) |
| Moderate | 175 (62%) | 211 (67%) | 219 (61%) |
| Poor | 39 (14%) | 39 (12%) | 57 (16%) |
| PR status | |||
| Negative | 73 (26%) | 72 (23%) | NA |
| Positive | 182 (64%) | 220 (69%) | |
| Unknown | 28 (10%) | 25 (8%) | |
| HER2 status | |||
| Negative | 257 (91%) | 295 (93%) | 316 (88%) |
| Positive | 26 (9%) | 22 (7%) | 42 (12%) |
| Adjuvant chemotherapy | |||
| No | 283 (100%) | 317 (100%) | 243 (68%) |
| Yes | 0 | 0 | 115 (32%) |
| Distant recurrence | |||
| Overall | 56 (100%) | 33 (100%) | 57 (100%) |
| Early (≤5 y) | 27 (48%) | 13 (39%) | 34 (60%) |
| Late (>5 y) | 29 (52%) | 20 (61%) | 23 (40%) |
| BCI groups | |||
| Low | 156 (55%) | 202 (64%) | 196 (55%) |
| Intermediate | 75 (27%) | 65 (20%) | 78 (22%) |
| High | 52 (18%) | 50 (16%) | 84 (23%) |
Abbreviation: NA, not available.